AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04426201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same number, volume and frequency of IM administration of saline
Study NCT01043146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COR-1
Description: single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
Study NCT01043146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous 0.9 % NaCl
Study NCT03234777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whiteboard animation video
Description: Developed via qualitative research with parents of children with acute gastroenteritis.
Study NCT03234777 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Regular video
Description: Developed by CDC
Study NCT03568539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: IBI308 200mg IV infusion, every 3 weeks.
Study NCT04270019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Standard solution of sterile normal saline.
Study NCT04547387 — intervention group
Intervention type: DEVICE
Intervention: Trans-carotid access revascularization with MicroNET covered stent implantation
Description: Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
Study NCT05515172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks.
Study NCT01690026 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivation interviewing based brief intervention
Study NCT03475888 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)
Description: Implantation of Medtronic Reveal LINQ™ ICM
Study NCT03881631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program
Description: Group-based intervention
Study NCT03881631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Well Program
Description: Group-based intervention
Study NCT01690026 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Intervention
Study NCT00101712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT00101712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vildagliptin Placebo
Study NCT05291026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile phone-based health information
Description: health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
Study NCT02597868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
Study NCT02597868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Description: endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
Study NCT00473473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Dichromate (Homeopathy)
Description: twice daily with an interval of 12 hours, for a period of up to 14 days
Study NCT00473473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo homeopathic remedy
Description: identical to treatment without active component
Study NCT05041946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given PO
Study NCT05041946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Sugar Pill)
Description: Given PO
Study NCT00409864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary stenting, Percutaneous biliary stenting
Description: percutaneous 10 F stent, endoscopic 10 F stent insertion
Study NCT00331214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone patch (300 mcg/day), patch changed twice a week for six months
Study NCT00331214 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo patch
Description: placebo patch replaced every 3-4 days for 6 months
Study NCT03545789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-958
Description: Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
Study NCT01244100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 fasted
Description: Fasted state
Study NCT02556827 — intervention group
Intervention type: OTHER
Intervention: Obtaining a blood sample
Description: Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
Study NCT02556827 — intervention group
Intervention type: DEVICE
Intervention: Reflectance confocal microscopy
Description: 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
Study NCT02556827 — intervention group
Intervention type: DEVICE
Intervention: Sebumeter
Description: Sebum rate at forehead and right cheek were evaluated with sebumeter
Study NCT02556827 — intervention group
Intervention type: DEVICE
Intervention: Video dermoscopy
Description: Dermoscopic photoaging scale were assessed by using video dermoscopy.
Study NCT04467931 — intervention group
Intervention type: DRUG
Intervention: ACEI/ARB
Description: Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
Study NCT04467931 — intervention group
Intervention type: DRUG
Intervention: Non-ACEI/ARB
Description: Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
Study NCT04467931 — intervention group
Intervention type: DRUG
Intervention: ACEI
Description: Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
Study NCT04467931 — intervention group
Intervention type: DRUG
Intervention: ARB
Description: Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
Study NCT03347188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.
Study NCT03347188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study NCT01317381 — intervention group
Intervention type: PROCEDURE
Intervention: Observational
Description: Blood draw
Study NCT03403374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Administered by SC injection via autoinjector (AI)/pen
Study NCT02219347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DMARD cessation
Description: Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
Study NCT01681017 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HBB/ENC Training and Equipment
Description: See the detailed description section
Study NCT01681017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HBB/ENC supplies
Description: Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
Study NCT01244100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 fed
Description: Fed state
Study NCT00651677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAL proctectomy
Description: Hand-assisted laparoscopic proctectomy
Study NCT02330484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to patients based on their own HbA1c improvement
Description: Give incentives to patients based on their own HbA1c improvement
Study NCT02330484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to physician based on their patient's HbA1c improvement
Description: Give incentives to physician based on their patient's HbA1c improvement
Study NCT00791310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucis
Description: FDG injected i.v
Study NCT00651677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: straight laparoscopic proctectomy
Description: straight laparoscopic proctectomy
Study NCT04750603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate (FF)/Vilanterol (VI)
Description: Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
Study NCT04750603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol
Description: Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
Study NCT00651677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-assisted laparoscopic proctectomy
Description: hand-assisted laparoscopic proctectomy
Study NCT00651677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SL Proctectomy
Description: Straight laparoscopic proctectomy
Study NCT00586274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD34 selected haploidentical PBSCT
Description: Infusion of CD34 selected haploidentical PBSCT
Study NCT00586274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: day -8 through day -4 Fludarabine 30 mg/m\^2
Study NCT00586274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell infusion
Description: At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are > 1000/ul.~Dose level -1 (1 x 10\^3 T cells/Kg); Dose level 1 (1 x 10\^4 T cells/Kg); Dose level 2 (1 x 10\^5 T cells/Kg); Dose level 3 (1 x 10\^6 T cells/Kg); Dose level 4 (5 x 10\^6 T cells/Kg)
Study NCT00586274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath 1h
Description: 10 mg iv over 4 hours day-8 through day-6
Study NCT00586274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD45
Description: anti-CD45 400 ug/kg over 6 hours day -5 through day -2
Study NCT00438425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Portfolio - Intensive
Description: Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
Study NCT00438425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Portfolio - Routine
Description: Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
Study NCT00438425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control (low saturated fat therapeutic diet)
Description: Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
Study NCT02148809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1mL of I-131 Human Serum Albumin is injected prior to the measurements
Study NCT02550054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epo
Description: Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
Study NCT02550054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
Study NCT02127476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6640
Description: Single ascending dose and multiple ascending doses administration
Study NCT02127476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Single ascending dose and multiple ascending doses administration
Study NCT01793740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed
Description: Computer based program that aims to improve children's memory, attention, and processing speed.
Study NCT03453385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: An e-cigarette and four weeks of e-liquid provided to participants.
Study NCT03999944 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: positive airway pressure system
Description: Positive Airway Pressure System
Study NCT03033732 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
Study NCT03033732 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine-Naloxone
Description: Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
Study NCT02518243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's answer with non pharmacological therapeutic
Description: Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games
Study NCT00504920 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
Study NCT01886469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-B
Description: d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
Study NCT01886469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-C
Description: d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
Study NCT01886469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-E
Description: d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
Study NCT03658941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No dural tenting techniques
Description: Not applying dural tenting sutures during closure of a craniotomy
Study NCT03658941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural tenting techniques
Description: Applying at least 3 dural tenting sutures during closure of a craniotomy
Study NCT01366196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Description: Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
Study NCT01209728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/ethanol (blinded)
Description: Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
Study NCT00107783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone (NTBC)
Description: Treatment
Study NCT04615897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new tecnology intervention
Description: The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes.
Study NCT01114152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: IV Formulation
Study NCT01114152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Formulation
Study NCT02187705 — intervention group
Intervention type: DRUG
Intervention: Telmisartan tablets
Description: All patients were treated with different doses of telmisartan for 14 days
Study NCT00641303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Given weekly for 8 sessions
Study NCT00641303 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Given weekly for 8 sessions
Study NCT03897504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap
Description: the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.